Rare Disease Genetic Testing
Africa · 2 shared keywords
Updated
Reviewed by Chandani Patel
Africa Rare Disease Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Technology, Patient, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$65.7 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $31.4 Mn | — | — |
| 2025 (base) | $35.2 Mn | +$3.9 Mn | — |
| 2026 (forecast) | $39.6 Mn | +$4.4 Mn | +12.4% |
| 2027 (forecast) | $44.5 Mn | +$4.9 Mn | +26.3% |
| 2028 (forecast) | $50.1 Mn | +$5.5 Mn | +42% |
| 2029 (forecast) | $56.3 Mn | +$6.2 Mn | +59.6% |
| 2030 (forecast) | $63.2 Mn | +$7.0 Mn | +79.4% |
| 2031 (forecast) | $71.1 Mn | +$7.8 Mn | +101.6% |
| 2032 (forecast) | $79.9 Mn | +$8.8 Mn | +126.7% |
| 2033 (forecast) | $89.8 Mn | +$9.9 Mn | +154.8% |
| 2034 (forecast) | $100.9 Mn | +$11.1 Mn | +186.3% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $35.2 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $100.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 12.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Technology, patient and end user (see all) |
| Key players | GeneDx, CENTOGENE, Invitae, FDNA, Illumina, Inc. (see all) |
| Regulator in Africa | AMASource: African Union, African Medicines Agency treaty. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Rare disease diagnostics help find the cause of rare conditions faster, using genetic tests, biomarkers and AI tools that read symptoms.
Key segments of the rare Disease Diagnostics market include technology (Genetic Sequencing, Biochemical Tests and AI Symptom Matching) and patient (Pediatric and Adult).
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the rare Disease Diagnostics market. More countries now have national rare disease plans.
Newborn genome screening, gene therapies and access programmes in emerging markets give the rare Disease Diagnostics market strong growth.
Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the rare Disease Diagnostics market.
The rare Disease Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
The African Medicines Agency (AMA) treaty covers medical devices and diagnostics as well as medicines; national regulators still approve products.[1] In some of the countries we cover here, medical devices are regulated by EDA (Egypt)[2], PPB (Kenya)[3], SAHPRA (South Africa)[4] and NAFDAC (Nigeria)[5]. How care is paid for in some of these countries: universal health insurance (Egypt)[6], the SHA (Kenya)[7], planned National Health Insurance (South Africa)[8] and out of pocket and the NHIA (Nigeria)[9].
[1] African Union, African Medicines Agency treaty. Checked 14 Nov 2026.
[2] Egyptian Drug Authority. Checked 14 Nov 2026.
[3] Pharmacy and Poisons Board. Checked 14 Nov 2026.
[4] South African Health Products Regulatory Authority. Checked 14 Nov 2026.
[5] NAFDAC. Checked 19 Nov 2026.
[6] Universal Health Insurance Authority. Checked 14 Nov 2026.
[7] Social Health Authority. Checked 14 Nov 2026.
[8] National Department of Health. Checked 14 Nov 2026.
[9] National Health Insurance Authority (NHIA). Checked 19 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how rare Disease Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Africa.
What doctors and scientists are doing in Rare Disease Diagnostics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Africa · 2 shared keywords
Africa
Africa
Africa
Africa
Africa
Pharmaceuticals · Africa
Digital Health · Africa
Pharmaceuticals · Africa
Healthcare Services · Africa
Pharmaceuticals · Africa
Healthcare Services · Africa